Stéphane Bancel

From Wikipedia, the free encyclopedia

Stéphane Bancel
Stephane Bancel.png
Stéphane Bancel
Born (1972-07-20) 20 July 1972 (age 49)
Marseille, France
EducationCentraleSupélec
University of Minnesota
Harvard Business School
OccupationBusinessman
Known forCEO and 9% owner, Moderna
Term2013–
Children2

Stéphane Bancel (born July 20, 1972) is a French billionaire businessman. He is the chief executive officer (CEO) of the American pharmaceutical and biotechnology company Moderna, known for its COVID-19 vaccine. Before joining Moderna, Bancel was the CEO of French diagnostics company BioMérieux. Bancel is a partner at Flagship Pioneering, and has served on the boards of Indigo Agriculture, Boston's Museum of Science, and Qiagen. As of August 2021, his net worth was estimated at US$12.5 billion, owning a roughly 8% stake in Moderna.[1]

Early life[]

Bancel was born in Marseille, France, and earned master's degrees in engineering from CentraleSupélec of Paris-Saclay University (former École Centrale Paris) and the University of Minnesota.[2] He went on to earn an MBA from Harvard Business School.[3]

Career[]

Bancel was a sales director at Eli Lilly and Company, eventually becoming head of operations for Belgium.[3] In 2007, he became CEO of French diagnostics company BioMérieux.[3]

In 2011, Bancel joined Moderna, becoming CEO. Stat reported that Bancel led a highly secretive culture with little outside review of its science or research.[3]

Personal life[]

Bancel has two children.[4] In April 2020, with the Moderna share price rising on news of imminent phase 2 human trials for its potential COVID-19 vaccine, Bancel's stake of about 9% became worth over $1 billion.[2] He lives in Boston, Massachusetts.[1]

References[]

  1. ^ a b "Forbes profile: Stéphane Bancel". Forbes. Retrieved 14 August 2021.
  2. ^ a b Tognini, Giacomo (3 April 2020). "Moderna CEO Stéphane Bancel Becomes A Billionaire As Stock Jumps On Coronavirus Vaccine News". Forbes. Archived from the original on 3 April 2020. Retrieved 4 April 2020.
  3. ^ a b c d Garade, Damien (13 September 2016). "Ego, ambition, and turmoil: Inside one of biotech's most secretive startups". Stat. Archived from the original on 16 November 2020. Retrieved 18 May 2020.
  4. ^ "Story Details - Alumni - Harvard Business School". www.alumni.hbs.edu. Retrieved 2 December 2020.


Retrieved from ""